Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

Université Laval

$17,500.00

Evaluation of the sFlt-1/PlGF ratio in the prediction and management of preeclampsia: a case-cohort study

FY 2023-24

Summary
Preeclampsia (PE) is a hypertensive disorder affecting between 2% and 8% of pregnancies. Although its etiology is not fully understood, deep placental dysfunction is present in the majority of preterm and severe forms of PE. The associated placental dysfunction can lead to fetal complications such as growth restriction, and in the worst cases, fetal death. Placental dysfunction causes an imbalance of angiogenic factors (such as placental growth factor or PlGF) and anti-angiogenic factors (such as the soluble form of VEGF type 1 receptor or sFlt-1) circulating in maternal blood. In cases of abnormal placentation, high concentrations of sFlt-1 will be released, resulting in low concentrations of PlGF. Both sFlt-1 and PlGF levels are disrupted several weeks before the first clinical manifestations of PE. An increase in the sFlt-1/PlGF ratio would therefore be a precursor of PE and could be useful in clinical decision-making related to PE. Few studies have evaluated the ratio in the 2nd trimester, and few have considered the normal variation of markers during pregnancy. It is therefore hypothesized that the sFlt-1/PlGF ratio is an effective predictive tool for severe and early forms of PE from the 2nd trimester onwards. To test this hypothesis, a case-cohort study will be conducted using the Quebec Perinatal Biobank, including over 14,000 pregnancies and serum samples. The sFlt-1/PlGF ratio will be measured at the following gestational ages: 11-13; 15-16; 22-23; and 32-35 weeks. Furthermore, the ratio will be calculated for each form of PE (according to term and severity) at each of the gestational ages studied. This study is critical as it will lead to a better understanding of the clinical aspects of PE, as well as the development of preventive approaches.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
505987
Name
Demuth Brielle E
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluation of the sFlt-1/PlGF ratio in the prediction and management of preeclampsia: a case-cohort study
Programtype2
Studentship Programs
Orgnameinp2
Université Laval
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Angiogenic Factors; Antiangiogenic Factors; Biomarkers; Placental Dysfunction; Placental Growth Factor; Preeclampsia; Pregnancy; Sflt-1/Plgf Ratio; Soluble Fms-Like Tyrosine Kinase-1; Women Health
Abstract
Preeclampsia (PE) is a hypertensive disorder affecting between 2% and 8% of pregnancies. Although its etiology is not fully understood, deep placental dysfunction is present in the majority of preterm and severe forms of PE. The associated placental dysfunction can lead to fetal complications such as growth restriction, and in the worst cases, fetal death. Placental dysfunction causes an imbalance of angiogenic factors (such as placental growth factor or PlGF) and anti-angiogenic factors (such as the soluble form of VEGF type 1 receptor or sFlt-1) circulating in maternal blood. In cases of abnormal placentation, high concentrations of sFlt-1 will be released, resulting in low concentrations of PlGF. Both sFlt-1 and PlGF levels are disrupted several weeks before the first clinical manifestations of PE. An increase in the sFlt-1/PlGF ratio would therefore be a precursor of PE and could be useful in clinical decision-making related to PE. Few studies have evaluated the ratio in the 2nd trimester, and few have considered the normal variation of markers during pregnancy. It is therefore hypothesized that the sFlt-1/PlGF ratio is an effective predictive tool for severe and early forms of PE from the 2nd trimester onwards. To test this hypothesis, a case-cohort study will be conducted using the Quebec Perinatal Biobank, including over 14,000 pregnancies and serum samples. The sFlt-1/PlGF ratio will be measured at the following gestational ages: 11-13; 15-16; 22-23; and 32-35 weeks. Furthermore, the ratio will be calculated for each form of PE (according to term and severity) at each of the gestational ages studied. This study is critical as it will lead to a better understanding of the clinical aspects of PE, as well as the development of preventive approaches.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Demuth, Brielle E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~